SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis

Company Overview

SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, particularly immunotherapies and targeted treatments for patients with difficult-to-treat malignancies. The company’s research and development programs are designed to address cancers with significant unmet medical needs.

SELLAS’s lead immunotherapy candidate, galinpepimut-S (GPS), is a multi-peptide vaccine intended to stimulate the immune system against Wilms’ tumor 1 (WT1), a protein expressed in several types of cancer. The company has been evaluating GPS primarily in acute myeloid leukemia, including in the Phase 3 REGAL clinical trial for patients with relapsed or refractory disease.

The company is also developing SLS009, a selective cyclin-dependent kinase 9 (CDK9) inhibitor being studied in oncology indications, including acute myeloid leukemia and certain solid tumors. SELLAS conducts clinical development activities through collaborations and research programs intended to support the advancement of its pipeline in the United States and other markets. The company was formerly known as Galena Biopharma, Inc. and is led by President and Chief Executive Officer Angelos Stergiou, M.D., Sc.D.

Key Stats

• Today's Range: $11.15 to $11.92
• 50-Day Range: $11.04 to $15.46
• 52-Week Range: $1.39 to $15.88
• Volume: 4.65 million shs
• Average Volume: 5.25 million shs
• Market Capitalization: $2.29 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Hold

SELLAS Life Sciences Group Stock Analysis - MarketRank™

SELLAS Life Sciences Group scored higher than 17% of companies evaluated by MarketBeat, and ranked 837th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.6 / 5
• Analyst Rating: Hold

Consensus Rating

SELLAS Life Sciences Group has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Downside Risk

SELLAS Life Sciences Group has a consensus price target of $10.00, representing about 11.8% downside from its current price of $11.34.

Amount of Analyst Coverage

SELLAS Life Sciences Group has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

SELLAS Life Sciences Group has a P/B Ratio of 24.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

27.66% of the float of SELLAS Life Sciences Group has been sold short.

Short Interest Ratio / Days to Cover

SELLAS Life Sciences Group has a short interest ratio ("days to cover") of 9.45.

Change versus previous month

Short interest in SELLAS Life Sciences Group has recently decreased by 6.67%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SELLAS Life Sciences Group does not currently pay a dividend.

Dividend Growth

SELLAS Life Sciences Group does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

SELLAS Life Sciences Group has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for SELLAS Life Sciences Group this week, compared to 4 articles on an average week.

Search Interest

27 people have searched for SLS on MarketBeat in the last 30 days. This is an increase of 4% compared to the previous 30 days.

MarketBeat Follows

Only 8 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.30% of the stock of SELLAS Life Sciences Group is held by insiders.

Percentage Held by Institutions

17.38% of the stock of SELLAS Life Sciences Group is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SLS
• CIK: 1390478
• Web: www.sellaslifesciences.com
• Phone: (646) 200-5278
• Fax: 441-400-2875
• Employees: 13
• Year Founded: 2006

Price Target and Rating

• Average Price Target for SELLAS Life Sciences Group: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: -11.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -35.91%
• Return on Assets: -33.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.83
• Quick Ratio: 18.83

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.46 per share
• Price / Book: 24.65

Miscellaneous

• Outstanding Shares: 201,950,000
• Free Float: 199,321,000
• Market Cap: $2.29 billion
• Optionable: Not Optionable
• Beta: 2.56